| Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study |
307 |
| Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis |
282 |
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial |
237 |
| Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 A Systematic Analysis for the Global Burden of Disease Study |
228 |
| Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer |
149 |
| Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy |
142 |
| Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis |
125 |
| Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial |
106 |
| Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer |
105 |
| Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study |
102 |
| Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial |
99 |
| Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis |
95 |
| Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib |
95 |
| Assessment of Ga-68-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial |
90 |
| Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade |
87 |
| Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis |
78 |
| Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial |
77 |
| Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab |
74 |
| Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial |
73 |
| Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial |
73 |
| Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study |
72 |
| Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel |
70 |
| Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer |
68 |
| Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial |
67 |
| Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial |
67 |
| Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016 |
67 |
| Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer |
65 |
| Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis |
64 |
| Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer |
62 |
| Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer |
61 |
| Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma |
60 |
| Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Non metastatic Breast Cancer |
60 |
| Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology A Prospective Blinded Multicenter Study |
60 |
| Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy |
60 |
| Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial |
58 |
| Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial |
58 |
| Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial |
57 |
| Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality |
56 |
| Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer |
55 |
| Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review |
54 |
| Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014 |
54 |
| Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer The KLASS-01 Randomized Clinical Trial |
53 |
| Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial |
53 |
| Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study |
52 |
| Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies |
51 |
| Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast |
51 |
| Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer |
50 |
| Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial |
50 |
| Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase Open-label VE-BASKET Study |
49 |
| Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women |
48 |
| Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion A Randomized Clinical Trial |
47 |
| Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer |
45 |
| Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial |
45 |
| Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial |
44 |
| Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer The NRG Oncology RTOG 0126 Randomized Clinical Trial |
44 |
| Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer |
44 |
| Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers A Systematic Review and Meta-analysis |
44 |
| Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial |
43 |
| Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women |
43 |
| Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial |
43 |
| Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial |
43 |
| Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial |
42 |
| Current Landscape of Immunotherapy in Breast Cancer: A Review |
41 |
| Evaluating an Intervention to Improve Communication Between Oncology Clinicians and Patients With Life-Limiting Cancer: A Cluster Randomized Clinical Trial of the Serious Illness Care Program |
40 |
| Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial |
39 |
| Association Between Aspirin Use and Risk of Hepatocellular Carcinoma |
39 |
| Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer |
39 |
| Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors |
39 |
| Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 Analysis of a Phase 1/2 Study |
38 |
| Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer Findings From the NRG Oncology RTOG 0618 Trial |
38 |
| Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers |
37 |
| Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer |
37 |
| Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology |
36 |
| Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial |
36 |
| Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial |
35 |
| EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer |
35 |
| Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer |
35 |
| Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial |
35 |
| Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model |
34 |
| Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing |
34 |
| Comparison of Insurance Status and Diagnosis Stage Among Patients With Newly Diagnosed Cancer Before vs After Implementation of the Patient Protection and Affordable Care Act |
34 |
| Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study |
33 |
| A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review |
32 |
| Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines |
32 |
| Safety and Efficacy of BIND- a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer A Phase 2 Clinical Trial |
31 |
| Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer |
31 |
| Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer |
31 |
| Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density |
30 |
| Propranolol for Off-label Treatment of Patients With Melanoma Results From a Cohort Study |
30 |
| Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors |
30 |
| Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma |
30 |
| Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer |
30 |
| Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide An Analysis From the NRG Oncology/RTOG 0424 Trial |
30 |
| Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial |
30 |
| Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 |
29 |
| Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma A Phase 2 Randomized Clinical Trial |
29 |
| Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial |
29 |
| Carfilzomib-Associated Cardiovascular Adverse Events A Systematic Review and Meta-analysis |
28 |
| Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer |
28 |
| Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial |
27 |
| Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial |
27 |
| Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status |
27 |
| Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis |
27 |
| Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer |
26 |
| Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer |
26 |
| Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 |
25 |
| Targeted Alpha Therapy, an Emerging Class of Cancer Agents A Review |
25 |
| A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification |
25 |
| Trends in Cancer Survival by Health Insurance Status in California From 1997 to 2014 |
25 |
| Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation |
25 |
| Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial |
24 |
| Monthly High-Dose Vitamin D Supplementation and Cancer Risk A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial |
24 |
| Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density |
24 |
| Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Phase 1b Results From the JAVELIN Solid Tumor Trial |
24 |
| Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity |
24 |
| Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection |
23 |
| Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer |
23 |
| Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis The CALGB 89803/Alliance Trial |
23 |
| Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial |
23 |
| Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma |
22 |
| Fiber Intake and Survival After Colorectal Cancer Diagnosis |
22 |
| Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer |
22 |
| Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage A Phase 2 Clinical Trial |
22 |
| Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials |
22 |
| Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial |
22 |
| Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma |
22 |
| Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Review |
21 |
| Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer A Phase 2 Clinical Trial |
21 |
| Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial |
21 |
| Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction |
21 |
| Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer |
21 |
| Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix A Randomized Clinical Trial |
20 |
| Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer Long-term Outcomes From a Phase 1 Study |
20 |
| Association of Exercise With Mortality in Adult Survivors of Childhood Cancer |
20 |
| Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers |
20 |
| First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis |
20 |
| Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer |
20 |
| Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma Pooled Analysis of 4 Randomized Clinical Trials |
19 |
| Effect of a Lay HealthWorker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer A Randomized Clinical Trial |
19 |
| Factors Associated With Age Disparities Among Cancer Clinical Trial Participants |
19 |
| Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma |
19 |
| Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women |
19 |
| Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome |
19 |
| Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials |
18 |
| Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers |
18 |
| Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial |
18 |
| Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins |
18 |
| Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trial |
17 |
| Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection |
17 |
| Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer |
17 |
| Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial |
17 |
| Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers |
17 |
| Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma |
17 |
| Incidence of Diabetes After Cancer Development A Korean National Cohort Study |
17 |
| A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer |
17 |
| Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis |
17 |
| Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial |
17 |
| Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer |
16 |
| Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer |
16 |
| Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia |
16 |
| Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma |
16 |
| Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women |
16 |
| Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers |
16 |
| National and State Estimates of Lost Earnings From Cancer Deaths in the United States |
16 |
| Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse |
16 |
| Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index A Secondary Analysis of a Randomized Clinical Trial and Observational Study |
16 |
| Interventions to Improve Oral Chemotherapy Safety and Quality A Systematic Review |
16 |
| Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis |
16 |
| Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer An Initial Report From the Surveillance, Epidemiology, and End Results Program |
16 |
| Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices |
16 |
| Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial |
16 |
| Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting |
15 |
| Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis A Systematic Review and Meta-analysis |
15 |
| Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival |
15 |
| Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma |
15 |
| Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer |
15 |
| Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers A Systematic Review and Meta-analysis |
14 |
| HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer |
14 |
| Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial |
14 |
| Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis |
14 |
| Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors |
14 |
| Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases |
14 |
| Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults |
14 |
| Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era |
14 |
| Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker forMetastatic Castration-Resistant Prostate Cancer |
14 |
| Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration |
14 |
| Therapeutic Options for Neuroendocrine Tumors A Systematic Review and Network Meta-analysis |
14 |
| Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer The MANTA Phase 2 Randomized Clinical Trial |
14 |
| Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status |
14 |
| Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas Insights for Personalized Therapy |
13 |
| Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia |
13 |
| Overall Mortality After Diagnosis of Breast Cancer in Men vs Women |
13 |
| Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer |
13 |
| Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer A Randomized Clinical Trial |
13 |
| Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome |
13 |
| Optimizing Cancer Treatment Using Game Theory A Review |
13 |
| Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma A Review |
13 |
| Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma A Review |
13 |
| Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer A Randomized Clinical Trial |
13 |
| Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer |
12 |
